Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04456231
Other study ID # 126
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date September 2020
Est. completion date June 2021

Study information

Verified date September 2020
Source Johannes Gutenberg University Mainz
Contact Helmut Neumann, Prof. Dr.
Phone +4917866516595
Email helmut.neumann@unimedizin-mainz.de
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Patients presenting for colonoscopy at one of the participating centers will be asked to participate in the present study after careful evaluation of inclusion and exclusion criteria. Before inclusion, all patients have to sign the written informed consent. All participating patients will receive PLENVU, a well-known and approved bowel preparation agent. Patients are randomly assigned in two groups. Patients in group 1 are informed in traditional way on how to use the bowel preparation agent. This way includes discussion with the physician and nurse on how to use the bowel preparation agent and a written documentation, highlighting the individual steps again. Patients in group 2 will receive in addition a QR-code referring to an App, available for free in all App stores, explaining to the patient in detail when and how to use the bowel preparation agent. The patient is receiving the same questionnaire (please see attached) in both groups and asked to bring the filled form on the day of the examination. Endoscopy is performed in standard way and effectiveness of the bowel preparation is specifically highlighted by the physician on the documentation report. Finally, data is analyzed regarding effectiveness of the QR code regarding patient satisfaction, acceptability and quality of the bowel preparation.


Description:

Patient education is of paramount importance for high acceptance and an adequate bowel preparation. Using the QR code directly referring to the App for bowel preparation with PLENVU might accelerate the discussion between the medical doctor and the patient and might also improve the acceptance rate of the patients for the bowel preparation finally leading to a more enhanced and effective bowel-preparation.

Patients undergoing screening or surveillance endoscopy will be prospectively included and randomly assigned to one of the following groups: Group 1: App; Group 2: no-App Study end points addressed below are prospectively assessed and evaluated for any significant changes.


Recruitment information / eligibility

Status Recruiting
Enrollment 404
Est. completion date June 2021
Est. primary completion date January 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria:

- • Screening or surveillance colonoscopy

- Age 18-85 years

- Written informed consent

Exclusion Criteria:

- • Pregnancy or lactating

- Lower gastrointestinal bleeding with hemodynamic instability

- Bowel obstruction

- ASA >3

- Not sufficiently corrected anticoagulation disorders

- Plenvu must not be taken:

- if you are allergic (hypersensitive) to the active ingredients or any of the other ingredients of this medicine;

- if you have a blockage (obstruction) in the digestive tract.

- if you have a breakthrough (perforation) in the wall of the digestive tract;

- if you suffer from intestinal obstruction (Ileus);

- if you suffer from a disturbance of gastric emptying (e.g. gastroparesis, gastric retention);

- if you suffer from phenylketonuria. Phenylketonuria is a congenital metabolic disease in which phenylalanine cannot be processed by your body. Plenvu contains aspartame as a source of phenylalanine;

- if you suffer from glucose-6-phosphate dehydrogenase deficiency;

- if you suffer from acute colon enlargement (toxic megacolon).

- Warnings and precautions

o You should tell your doctor about the following circumstances before taking Plenvu:

- if you have heart problems and/or arrhythmias;

- if you have kidney problems and/or suffer from dehydration;

- if you have stomach or intestinal problems, including intestinal inflammation;

- if you have difficulty or discomfort when swallowing liquids;

- if you have high or low levels of electrolyte (e.g. sodium, potassium);

- if you have other diseases (e.g. convulsions).

- Pregnancy and lactation o There are no data on the use of Plenvu during pregnancy or lactation and is therefore not recommended.

Study Design


Intervention

Drug:
Plenvu
Patients will receive Plenvu for preparation of endoscopy

Locations

Country Name City State
Germany Dr. Helmut Neumann Bad Salzuflen Northrine-Westfalia

Sponsors (1)

Lead Sponsor Collaborator
Johannes Gutenberg University Mainz

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Boston Bowel Preparation Standard (BBPS) Bowel preparation according to international Standard, 1 is bad, 9 is very good, how many patients can Achieve BBPS with 9? 1 day
Primary Adenoma detection rate (ADR) How many adenomas will be detected during endoscopy 1 day
Primary Polyp detection rate (PDR) How many polyps will be detected during endoscopy 1 day
Primary time exposure to explain bowel preparation How much time will patients Need for preparation and how much time for discussing with the doctors 1 day
Secondary Number of patients who are satisfied with preparation How will doctors and patients like preparation with Plenvu and QR Code up to 1 month
Secondary Number of patients who Accept to repeat the examination (surveillance) How many patients will come back for another endoscopy up to 1 month
Secondary cecal intubation rate How many endoscopies will reach the ceacum 1 day
Secondary procedure time How Long will endoscopy take compared to Standard technique 3 hours
See also
  Status Clinical Trial Phase
Completed NCT04774562 - The Effect of Video-Assisted Discharge Education After Total Hip Replacement Surgery N/A
Completed NCT03426787 - Helping Empower Liver and Kidney Patients N/A
Not yet recruiting NCT05965986 - Preoperative Rehabilitation and Education Program N/A
Completed NCT05529732 - The Effect of Mobile Education on Anxiety and Activities of Daily Living N/A
Not yet recruiting NCT05088538 - The Effect of Quick Response Coded Teaching Plan, Patients With Total Knee Replacement N/A
Recruiting NCT05180721 - A Multi-level Intervention to Increase Access and Use of the Patient Portal N/A
Recruiting NCT06140043 - Augmented Reality for Orthognatic Surgery Patient Education Phase 2/Phase 3
Recruiting NCT06027333 - Self-efficacy and Well-being of Patients With Fibrotic Interstitial Lung Disease
Completed NCT02718807 - Rapid Prototyping Models for Patient Education
Completed NCT03856320 - Teaching Obesity Treatment Options to Adult Learners Trial N/A
Completed NCT04829721 - Pelvic Floor Disorder Assessment of Knowledge and Symptoms: an Educational Model in Spanish-Speaking Women N/A
Completed NCT03743753 - Educational Session To Optimize Patient's Breast Reconstruction Experience at McMaster N/A
Active, not recruiting NCT04023500 - Supporting Oral Self-care of Patients With Periodontitis Through Motivational Interview N/A
Recruiting NCT05960734 - AI-driven Quality Assessment of YouTube Videos Providing Information on Incontinence After Cancer Surgery.
Not yet recruiting NCT06310720 - Postpartum Video Education in High Risk Populations N/A
Active, not recruiting NCT05609227 - Effect of Mobile Application on Supportive Care Needs and Quality of Life Patients Undergoing Hematopoietic Stem Cell Transplantation N/A
Completed NCT05088551 - The Effect of the Educational Plan Prepared According to the Health Literacy Levels of Patients N/A
Completed NCT03633136 - A Randomized Controlled Trial of a Pre-Transplant Education Intervention N/A
Completed NCT05159726 - Postpartum Video Education N/A
Completed NCT04850209 - The Impact of WeChat Group Patient Education on the Eradication Rate of Helicobacter Pylori N/A